A form of immunotherapy known as CAR-T cell therapy has demonstrated significant success in treating patients with stiff person syndrome (SPS), a progressive neurological condition. This treatment, which trains the body's immune system to target and eliminate disease-causing cells, was administered in a recent clinical trial.
Two participants in the US trial, Jonathan Walden and Shari St Germain, recovered essential everyday capabilities that SPS had previously taken away. Mr. Walden, who had relied on family for help with walking and daily tasks, has since resumed working and participating in activities like hunting and fishing. Ms. St Germain, diagnosed in 2021, experienced improvements such as being able to walk on a treadmill again after the treatment.
Dr. Anastasia Zekeridou, a neurologist and researcher at Mayo Clinic, which led the trial, noted the striking degree of improvement in some patients. Dr. Sean Pittock, chairman of the department of neurology at Mayo Clinic, highlighted the potential of CAR-T therapy in autoimmune neurological diseases, offering hope for SPS patients and those with other immune-mediated neurological conditions.
SPS is a rare neurological disorder that gradually worsens, causing physical stiffness throughout the body. It is believed to be an autoimmune condition, affecting an estimated 8,000 people worldwide, with symptoms typically developing between the ages of 20 and 60.